Psychedelics for Depression: MindBio and Enveric’s Joint Efforts [TDR]
Wednesday, May 15, 2024 1 min read
Key Takeaway: MindBio Therapeutics and Enveric Biosciences are collaborating to develop treatments for neuropsychiatric disorders using microdosing psychedelics. Their efforts focus on novel psilocin prodrug candidates, aiming to provide mental health solutions without the hallucinogenic effects typically associated with psychedelics. This partnership marks a significant step in the field of psychedelic medicine.
Price reaction · baseline $147.69 (2024-05-14 close) · hit pre-market · 4 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
-4%
Market Sentiment Analysis
POSITIVE FACTORS
Collaboration aims to advance treatments for neuropsychiatric disorders.
Utilizes microdosing psychedelics to manage mental health.
Focus on novel psilocin prodrug candidates.
Full Press Release Details
MindBio Therapeutics (CNSX: MBIO) and Enveric Biosciences (NASDAQ: ENVB) are collaborating to advance treatments for neuropsychiatric disorders through microdosing psychedelics, such as their novel psilocin prodrug candidates. This partnership represents a significant move toward utilizing psychedelic medicines to manage mental health disorders without the typical hallucinogenic effects.
Full Article >>
Frequently Asked Questions
What is the focus of MindBio and Enveric's collaboration?
Their collaboration focuses on advancing treatments for neuropsychiatric disorders using microdosing psychedelics.
What type of psychedelics are being used in the partnership?
They are utilizing novel psilocin prodrug candidates for their treatments.
What is microdosing in the context of psychedelics?
Microdosing involves using sub-hallucinogenic doses of psychedelics to manage mental health disorders.